IP Library Granted Patent US 8,946,287
Granted Patent B2
US 8,946,287 · App. 12/519,263 · Granted Feb 3, 2015

Chemotherapeutic flavonoids, and syntheses thereof

Inventors: Mark S. Cushman (West Lafayette, IN); John M. Pezzuto (Hilo, HI); Arup Mati (Purga Medinipur, IN)
Assignee: Purdue Research Foundation
C07D311/32C07D311/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,946,287
App. No.
12/519,263
Granted
Feb 3, 2015
Kind
B2
Abstract

Substituted flavonoid compounds, and pharmaceutical formulations of flavonoid compounds are described. Also described are processes for preparing flavonid compounds, as are methods for treating cancer in mammals using the described flavonoid compounds or pharmaceutical formulations thereof.

Claims (28)

1. A compound of the formula

and pharmaceutically acceptable salts thereof, wherein:

bond a is a single bond;

R a represents 2-4 substituents where at least 2 of said substituents are adjacent substituents and are taken together to form alkylenedioxy, and where any remaining substituents are each independently selected from the group consisting of halo, hydroxy, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkoxy, cyano, nitro, optionally substituted alkylthio, optionally substituted alkylsulfonyl, carboxylic acid and derivatives thereof, and sulfonic acid and derivatives thereof; and

R c represents 1-4 substituents each of which is independently selected from the group consisting of halo, hydroxy, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkoxy, cyano, nitro, optionally substituted alkylthio, optionally substituted alkylsulfonyl; carboxylic acid and derivatives thereof, and sulfonic acid and derivatives thereof;

provided that at least one of R c is alkenyl; and

provided that when R a is 7-hydroxy and alkylenedioxy or 7-alkoxy and alkylenedioxy, R c is not 4′-hydroxy or 4′-alkoxy.

2. The compound of claim 1 wherein R a represents 2 adjacent substituents taken together to form alkylenedioxy.

3. The compound of claim 2 wherein R c includes one or more (3-methylbut-2-enyl) groups.

4. A pharmaceutical composition for treating a patient in need of relief from breast cancer, the composition comprising:

(a) the compound of claim 1 ; and

(b) one or more pharmaceutically acceptable carriers, diluents, and excipients therefor;

where the compound is present in an amount effective for treating the patient.

5. The composition of claim 4 wherein R a includes one or more alkoxy groups.

6. The composition of claim 5 wherein R c also includes one or more alkoxy groups.

7. The composition of claim 6 wherein R c includes one or more (3-methylbut-2-enyl) groups.

8. A process for preparing a compound of the formula

from an enone intermediate, the process comprising: reacting a compound of the formula

with a compound of the formula

and

cyclizing the enone intermediate, wherein:

R a represents 2-4 substituents where at least 2 of said substituents are adjacent substituents and are taken together with the attached carbons to form alkylenedioxy, and where any remaining substituents are each independently selected from the group consisting of halo, hydroxy, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkoxy, cyano, nitro, optionally substituted alkylthio, optionally substituted alkylsulfonyl, carboxylic acid and derivatives thereof, and sulfonic acid and derivatives thereof; and

group consisting of halo, hydroxy, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkoxy, cyano, nitro, optionally substituted alkylthio, optionally substituted alkylsulfonyl, carboxylic acid and derivatives thereof, and sulfonic acid and derivatives thereof;

provided that at least one of R c is alkenyl; and

provided that when R a is 7-hydroxy and alkylenedioxy or 7-alkoxy and alkylenedioxy, R c is not-4′-hydroxy or 4′-alkoxy.

9. The process of claim 8 wherein the reacting step is conducted under Claisen-Schmidt conditions and the cyclizing step includes sodium acetate.

10. The process of claim 8 wherein the enone intermediate is of the formula

wherein R a and R c are as defined in claim 8 .

Assignments (2)
CONFIRMATORY LICENSE Recorded Feb 24, 2015
From: PURDUE UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 035072/0425 →
CONFIRMATORY LICENSE Recorded Nov 17, 2011
From: PURDUE UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 027244/0935 →
Continuity (2)
Provisional Application 60874550 · Dec 13, 2006
Related Publication 20100099755A1 · Apr 22, 2010